Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Landau

Showing results (141-150 of 184) with videos related to

Pageof 19
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2026
Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient SurveyNadine H Abdallah, Jay R Hydren, Mason S Barnes, et al.
American Journal of Hematology|January 28, 2023
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choiceVaishali Sanchorawala, Ashutosh D Wechalekar, Kihyun Kim, et al.
JACC. Cardiooncology|February 18, 2026
Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic ImpactOlayiwola Bolaji, Samantha Brown, Brian C Shaffer, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2018
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17pSandy W Wong, Ute Hegenbart, Giovanni Palladini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple MyelomaMalin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Blood|June 27, 2023
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trialMorie A Gertz, Adam D Cohen, Raymond L Comenzo, et al.
Transplantation and Cellular Therapy|October 1, 2022
Pilot Trial of Homebound Hematopoietic Cell TransplantationHeather J Landau, Evelyn Orlando, Elizabeth S Rodriguez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2020
Prognostic Factors for Postrelapse Survival after ex Vivo CD34<sup>+</sup>-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple MyelomaAlexandra Gomez-Arteaga, Gunjan L Shah, Raymond E Baser, et al.
Blood Neoplasia|July 12, 2026
CD8<sup>+</sup>CD38<sup>+</sup> T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlatesNezar Mehanna, Andriy Derkach, Billel Gasmi, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Pageof 19

Showing results (141-150 of 184) with videos related to

Sort By:
Pageof 19
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2026
Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient SurveyNadine H Abdallah, Jay R Hydren, Mason S Barnes, et al.
American Journal of Hematology|January 28, 2023
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choiceVaishali Sanchorawala, Ashutosh D Wechalekar, Kihyun Kim, et al.
JACC. Cardiooncology|February 18, 2026
Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic ImpactOlayiwola Bolaji, Samantha Brown, Brian C Shaffer, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2018
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17pSandy W Wong, Ute Hegenbart, Giovanni Palladini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple MyelomaMalin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Blood|June 27, 2023
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trialMorie A Gertz, Adam D Cohen, Raymond L Comenzo, et al.
Transplantation and Cellular Therapy|October 1, 2022
Pilot Trial of Homebound Hematopoietic Cell TransplantationHeather J Landau, Evelyn Orlando, Elizabeth S Rodriguez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2020
Prognostic Factors for Postrelapse Survival after ex Vivo CD34<sup>+</sup>-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple MyelomaAlexandra Gomez-Arteaga, Gunjan L Shah, Raymond E Baser, et al.
Blood Neoplasia|July 12, 2026
CD8<sup>+</sup>CD38<sup>+</sup> T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlatesNezar Mehanna, Andriy Derkach, Billel Gasmi, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Pageof 19